Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study
Open Access
- 1 January 2010
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 49 (4) , 418-422
Abstract
The objective of this study was to evaluate the safety of escalating up to 55 Gy within five weeks, the dose of external beam radiotherapy to the previous tumor site concurrently with a fixed daily dose of capecitabine, in patients with resected pancreatic cancer. Material and methods. Patients with resected pancreatic carcinoma were eligible for this study. Capecitabine was administered at a daily dose of 1600 mg/m 2. Regional lymph nodes received a total radiation dose of 45 Gy with 1.8 Gy per fractions. The starting radiation dose to the tumor bed was 50.0 Gy (2.0 Gy/fraction, 25 fractions). Escalation was achieved up to a total dose of 55.0 Gy by increasing the fraction size by 0.2 Gy (2.2 Gy/fraction), while keeping the duration of radiotherapy to five weeks (25 fractions). A concomitant boost technique was used. Dose limiting toxicity (DLT) was defined as any grade>3 hematologic toxicity, grade>2 liver, renal, neurologic, gastrointestinal, or skin toxicity, by RTOG criteria, or any toxicity producing prolonged (> 10 days) radiotherapy interruption. Results and discussion. Twelve patients entered the study (median age: 64 years). In the first cohort (six patients), no patient experienced DLT. Similarly in the second cohort, no DLT occurred. All 12 patients completed the planned regimen of therapy. Nine patients experienced grade 1-2 nausea and/or vomiting. Grade 2 hematological toxicity occurred in four patients. The results of our study indicate that a total radiation dose up to 55.0 Gy/5 weeks can be safely administered to the tumor bed, concurrently with capecitabine (1600 mg/m 2) in patients with resected pancreatic carcinoma.Keywords
This publication has 16 references indexed in Scilit:
- Intraoperative Radiation Therapy in Resected Pancreatic Carcinoma: Long-Term AnalysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Phase II Study of Capecitabine With Concomitant Radiotherapy for Patients With Locally Advanced Pancreatic Cancer: Up-Regulation of Thymidine PhosphorylaseThe Cancer Journal, 2007
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelinesSupportive Care in Cancer, 2004
- Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors1Journal of the American College of Surgeons, 2004
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004
- Long-Term Survival After Curative Resection for Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 1996
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
- Analysis of Failure After Curative Irradiation of Extrahepatic Bile Duct CarcinomaAnnals of Surgery, 1992
- Patterns of failure after curative resection of pancreatic carcinomaCancer, 1990